IMAB I-Mab
USHealthcareAs of 2026-03-17 09:30
Why IMAB matters now
I-Mab (IMAB) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.88 with -0.69% on the session and $542.0M in market capitalization; recent performance reads 1-month +0.00% and YTD +0.00%.
The latest financial table shown here is Q2 2025, with revenue of $0.00, net income of $-767.5K, and EPS of $-0.01. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -0.1%.
Additional event context on this page matters because analyst consensus is Buy with a median target of $7.50. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
15.43
P/S
0.00
EV/EBITDA
-36.16
DCF Value
$0.12
FCF Yield
-0.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-0.5%
ROA
-53.4%
ROIC
-94.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $0.00 | $-767.5K | $-0.01 |
| Q1 2025 | $0.00 | $-432.6K | $-0.04 |
| Q4 2024 | $0.00 | $-1.2M | $-0.02 |
| FY 2024 | $0.00 | $-22.2M | $-0.62 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$7.75
Target (Median)
$7.50
Target Range
$7.00 - $9.00
Related Stocks
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.46
I-Mab is a biopharmaceutical company, operating at the clinical stage, dedicated to the discovery, advancement, and commercialization of biologic therapies. Its core mission is to address critical medical needs in both oncology and autoimmune diseases. The company boasts a comprehensive pipeline of drug candidates. Among its most advanced programs, Eftansomatropin alfa, a long-acting human growth hormone, has successfully completed Phase 3 clinical trials for pediatric growth hormone deficiency. Similarly, Lemzoparlimab, a CD47 monoclonal antibody, has concluded its Phase 2 clinical evaluation. Other notable assets include Felzartamab, a CD38 antibody currently undergoing Phase 1b/2a development for membranous nephropathy. Both TJ107 and Efineptakin (a long-acting variant), recombinant human IL-7 therapies, are progressing through Phase 2 for cancer treatment-related lymphopenia and immunotherapy applications. The pipeline further comprises Enoblituzumab, a humanized B7-H3 antibody in Phase 2 for head and neck cancer and other malignancies; Uliledlimab, a CD73 antibody, also in Phase 2 for solid tumors; and TJ210, a monoclonal antibody against human C5aR1, which is in Phase 1 for cancer and autoimmune disorders. I-Mab's portfolio also features Plonmarlimab, a GM-CSF monoclonal antibody intended for inflammation and CRS-related therapies, alongside several specialized oncology agents: TJ-L14B (a PD-L1-based tumor-dependent T-cell engager for solid cancers), TJ-CD4B (a tumor-dependent T-cell engager for gastric and other cancers), TJ-L1IF (a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors), and TJ-C64B (a tumor-dependent T-cell engager for ovarian and other cancers). To bolster its development efforts, I-Mab has forged strategic alliances with leading industry partners, including AbbVie Ireland Unlimited Company, Sinopharm Group Co. Ltd., PT Kalbe Genexine Biologics, and Roche Diagnostics. Established in 2014, the company's headquarters are located in Shanghai, People's Republic of China.